Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Novel immunotherapy leads to complete regression of chemotherapy-resistant liver cancer in 3-year-old (opens in a new tab)

medicalxpress.com · 2026-09-10

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 5Not checkedA new report in the New England Journal of Medicine describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy.View evidenceHide evidence

As statedcomplete regression

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 5Not checkedThe patient was enrolled in the CARE study, a first-in-human, phase 1 trial evaluating glypican-3-specific chimeric antigen receptor (GPC3-CAR) T cells armed with interleukin-15 and -21.View evidenceHide evidence

As statedfirst-in-human, phase 1

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 5Not checkedAfter two infusions eight weeks apart, the child had a partial response after the first infusion and complete resolution of the metastatic disease after the second infusion.View evidenceHide evidence

As statedcomplete resolution

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 5Not checkedNo dose-limiting toxicities or cytokine release syndrome occurred, and complete regression continued one year after treatment.View evidenceHide evidence

As statedone year after treatment

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 5Not checkedThe article quotes the first author as saying the case shows a durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without systemic toxicity.View evidenceHide evidence

As stateddurable complete response

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 39 candidate papers

And 33 more candidates considered.